Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

LSD-belægning af serotonin 2A-receptoren i den menneskelige hjerne (dOccLS)

11. november 2026 opdateret af: Gitte Moos Knudsen, Copenhagen University Hospital, Rigshospitalet

Lysergsyrediethylamid Belægning af serotonin 2A-receptoren i den menneskelige hjerne

The investigators wish to quantify the relation between administered dose of lysergic acid diethylamide (LSD), plasma LSD levels, and occupancy at the serotonin 2A receptor (5-HT2AR) using [11C]CIMBI-36 positron emission tomography.

Studieoversigt

Status

Rekruttering

Betingelser

Detaljeret beskrivelse

Healthy participants will be administered one of a single dose of lysergic acid diethylamide (LSD) between 25 and 200 micrograms equivalent freebase. They will receive [11C]CIMBI-36 positron emission tomography (PET) scans at baseline and twice following LSD administration during peak and declining drug effects. PET scans will be acquired in a simultaneous PET/Magnetic Resonance Imaging (MRI) scanner which will also collect functional brain imaging data. Venous blood samples will be repeatedly drawn during acute drug effects for quantification of plasma LSD levels. Participants will also repeatedly rate their subjective drug intensity on a scale from 0 to 10 during acute drug effects. Together these data will inform the dose-binding relation of LSD at the serotonin (5-HT) 2A receptor, the primary site of action. This data will also inform the relation between 5-HT2A receptor binding by LSD and the induced subjective effects, as well as the effects on functional brain activity as measured with functional MRI.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

40

Fase

  • Tidlig fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Gitte M Knudsen, DMsc, MD
  • Telefonnummer: +45 35456720
  • E-mail: gmk@nru.dk

Undersøgelse Kontakt Backup

Studiesteder

      • Copenhagen, Danmark, 2100
        • Rekruttering
        • Neurobiology Research Unit, Rigshospitalet
        • Kontakt:
          • Gitte M Knudsen, DMSc
          • Telefonnummer: +45 35456720
          • E-mail: gmk@nru.dk
        • Underforsker:
          • Drummond E. McCulloch, BSc
        • Underforsker:
          • Patrick M. Fisher, PhD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

• Healthy individual between 18-75 years old

Exclusion Criteria:

  • Current or past history of primary psychiatric illness (The Diagnostic and Statistical Manual of Mental Disorders IV axis-I or World Health Organisation International Classification of Diseases-10 diagnostic classification)
  • Current or past history of primary psychiatric illness (The Diagnostic and Statistical Manual of Mental Disorders IV axis-I or World Health Organisation International Classification of Diseases-10 diagnostic classification) in a first degree relative (i.e., parents, siblings)
  • Current or past history of neurological disease, significant somatic condition/disease
  • Use of medication that could potentially influence results (e.g.., drugs that act on relevant components of the serotonin system or may interfere with metabolism of study drug)
  • Non-fluent Danish language skills
  • Profound visual or auditory impairments
  • Severe learning disability
  • Pregnancy on the scan date, verified by a pregnancy test (test omitted if confirmed that individual is post-menopausal)
  • Lactation (females)
  • Contraindications for magnetic resonance imaging (e.g., pacemaker, claustrophobia, etc.)
  • Contraindications for positron emission tomography
  • Alcohol or drug abuse
  • Allergy to administered compounds
  • Participant in research study with >10 millisievert exposure within the past year or significant occupational exposure to radioactive substances
  • Abnormal ECG (ECG indicating current or previous heart disease or predisposition to heart disease, e.g., QT prolongation) or use of QT prolonging medication
  • Use of psychedelic substance within the preceding six months
  • Blood donation up to three months before the study (i.e., more than 500ml of blood)
  • Head injury or concussion resulting in loss of consciousness for more than 2 min
  • Haemoglobin levels < 7.8 mmol/l for women and 8.4 mmol/l for men
  • Ferritin levels outside normal range (12-300 µg/L)
  • Body-weight < 50 kg or > 110kg
  • body-mass index > 35
  • Individual assessment by research staff deeming drug administration unsafe due to ethical or psychological circumstance of the participant

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: LSD dose-ranging group

All participants will receive between 25 and 200 micrograms of lysergic acid diethylamide equivalent as freebase, single blinded with respect to dose. Simultaneous PET/MR imaging will be performed during acute drug effects.

D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)

Andre navne:
  • LSD
  • d-LSD
  • LSD-25

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Plasma LSD - serotonin 2A receptor (5-HT2AR) occupancy relation
Tidsramme: Within 24 hours following drug administration

Occupancy will be estimated by comparing non-displaceable binding potential (BPND) values using baseline and intervention rescans as calculated using a simplified reference tissue model (SRTM). Occupancy values will be compared to plasma lysergic acid diethylamide (LSD) levels.

Within 24 hours following drug administration

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Subjective drug intensity - 5-HT2AR occupancy relation
Tidsramme: Within 24 hours following drug administration

Occupancy will be calculated as described above. Subjective drug intensity is collected during positron emission tomography (PET) scans by asking participants.

Within 24 hours following drug administration
fMRI network disintegration - 5-HT2AR occupancy relation
Tidsramme: Within 24 hours following drug administration

functional magnetic resonance imaging (fMRI) data will be used to estimate functional-network connectivity using a standard functional brain atlas. Then the relation between decreases in functional network connectivity and 5-HT2AR occupancy will be estimated.

Within 24 hours following drug administration
fMRI brain entropy - 5-HT2AR occupancy relation
Tidsramme: Within 24 hours following drug administration

fMRI brain entropy will be estimated by the shannon entropy of dynamic conditional correlation of within and between network connectivity as well as the lempel-ziv complexity of concatenated binarised blood-oxygen level dependent (BOLD) signals across regions. The relation between each of these measures with 5-HT2AR occupancy will be estimated.

Within 24 hours following drug administration
Cerebral perfusion - 5-HT2AR occupancy relation
Tidsramme: Within 24 hours following drug administration

Cerebral perfusion will be estimated using arterial spin labelling. The relation between this measure and 5-HT2AR occupancy will be estimated.

Within 24 hours following drug administration
Administered LSD dose - 5-HT2AR occupancy relation
Tidsramme: Within 24 hours following drug administration

Administered dose (25 to 200 mcg) will be compared with peak LSD occupancy to determine what doses produce maximal occupancy at the 5-HT2AR.

Within 24 hours following drug administration

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Hysteresis effect of 5-HT2AR binding
Tidsramme: Within 24 hours following drug administration

Estimated dose-occupancy curves derived from the first PET scan and second PET scan will be calculated separately to evaluate whether there are differences in estimated plasma level-occupancy relation at different timepoints following LSD administration which may indicate a hysteresis effect due to peripheral LSD metabolism without unbinding of LSD from the 5-HT2A receptor.

Within 24 hours following drug administration

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Gitte M Knudsen, DMsc, MD, Copenhagen University Hospital, Rigshospitalet

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. november 2023

Primær færdiggørelse (Anslået)

1. december 2027

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

14. februar 2023

Først indsendt, der opfyldte QC-kriterier

11. juli 2023

Først opslået (Faktiske)

19. juli 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner